New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 5, 2014
07:04 EDTTRVNTrevena initiates TRV734 clinical development
Trevena announced the initiation of its first Phase 1 trial for TRV734. TRV734 is being developed to optimize analgesia while minimizing on-target gastrointestinal and respiratory effects through its novel biased ligand mechanism at the mu-opioid receptor. TRV734 takes advantage of the same receptor specificity mechanism as does Trevena’s Phase 2 clinical candidate, TRV130. The main objective of this first-in-human trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single ascending doses of TRV734 in healthy subjects. The potentially efficacious dose range of TRV734 will also be evaluated using pupilometry, a validated biomarker for mu-opioid receptor engagement.
News For TRVN From The Last 14 Days
Check below for free stories on TRVN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
07:01 EDTTRVNTrevena granted composition of matter patent for TRV130
Trevena announced that the U.S. Patent and Trademark Office granted U.S. Patent No. 8,835,488, “Opioid receptor ligands and methods of using and making same.” The patent covers TRV130, compositions comprising TRV130, and methods of using TRV130 and is expected to provide patent coverage for TRV130 until at least 2032. Trevena currently is testing TRV130 for the treatment of postoperative pain in a Phase 2a/b clinical trial. Earlier clinical and preclinical data were published in the Journal of Clinical Pharmacology and the Journal of Pharmacology and Experimental Therapeutics.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use